Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241786 · ClinicalTrials.gov registry record · Phase 2
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL
A Phase 2 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01241786 is a Phase 2 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 5 participants.
The verdict
NCT01241786, a Phase 2 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
To determine the response to the combination of Revlimid (Lenalidomide)+ Vidaza (Azacitidine) in patients with relapsed/refractory CLL and SLL Hypothesis- lenalidomide's activity in combination with azacitidine may further enhance its activity and the durability of treatment response.
Interventions
- DRUG Azacitidine
- DRUG Revlimid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01241786
The ClinicalTrials.gov registry entry for NCT01241786 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT01241786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01241786 about?
NCT01241786 is a clinical study titled "Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL". To determine the response to the combination of Revlimid (Lenalidomide)+ Vidaza (Azacitidine) in patients with relapsed/refractory CLL and SLL Hypothesis- lenalidomide's activity in combination with azacitidine may further enhance its activity and the durability of treatment response.
What is the current status of trial NCT01241786?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01241786?
The interventions under investigation include: Azacitidine (DRUG), Revlimid (DRUG).
Who is sponsoring clinical trial NCT01241786?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.